Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
---|---|
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00297180 |
GW869682 causes glucose to be excreted in the urine. The purpose of this study is to see whether enough calories from glucose are excreted in the urine to cause weight loss.
Condition | Intervention | Phase |
---|---|---|
Obesity |
Drug: GW869682 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Single Group Assignment, Efficacy Study |
Official Title: | A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Weight Loss, Safety, Tolerability and Pharmacokinetics in Obese Subjects Following 12-Week Dosing of GW869682, an SGLT2 Inhibitor |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion criteria:
Exclusion criteria:
United States, Florida | |
GSK Investigational Site | |
Daytona Beach, Florida, United States, 32114 | |
United States, Louisiana | |
GSK Investigational Site | |
Baton Rouge, Louisiana, United States, 70808 | |
United States, Oregon | |
GSK Investigational Site | |
Portland, Oregon, United States, 97239 |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Responsible Party: | GSK ( Study Director ) |
Study ID Numbers: | KGO105858 |
Study First Received: | February 24, 2006 |
Last Updated: | October 15, 2008 |
ClinicalTrials.gov Identifier: | NCT00297180 History of Changes |
Health Authority: | United States: Food and Drug Administration |
weight loss obesity body composition hunger |
GW869682 sodium-dependent glucose transporter SGLT2 inhibitor |
Body Weight Signs and Symptoms Obesity Weight Loss |
Body Weight Changes Nutrition Disorders Overweight Overnutrition |
Body Weight Signs and Symptoms Obesity Weight Loss |
Body Weight Changes Nutrition Disorders Overweight Overnutrition |